Research programme: anti-cancer therapeutics- OncoResponse

Drug Profile

Research programme: anti-cancer therapeutics- OncoResponse

Alternative Names: anti-EMP2 diabody; Anti-EMP2 mAb; ONCR 201; PG 101

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California at Los Angeles
  • Developer OncoResponse
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action EMP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Glioblastoma

Most Recent Events

  • 07 Nov 2017 OncoResponse plans to file an IND application for ONCR 201 with the US FDA in USA for Breast cancer and Glioblastoma in 2019
  • 07 Nov 2017 Pharmacodynamics data from a preclinical study in Cancer released by OncoResponse
  • 07 Nov 2017 Paganini Biopharma has been acquired and merged into OncoResponse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top